Nowadays, continuous treatment has become more commonplace as opposed to the limited cycles of therapy to help relapsed/refractory multiple myeloma (rrMM) patients achieve and remain in remission. However, since patients in the relapsed/refractory (rr) state are generally older and frailer, they are less likely to tolerate more rigorous intravenous (IV) treatments over extended periods of time.¹ Oral therapy is the next generation of long-term rrMM management.¹ Thus far, ixazomib + lenalidomide + dexamethasone (IRd) is the first-and-only all-oral regimen proven for the treatment of rrMM patients. Its efficacy had been demonstrated in the TOURMALINE-MM1 study and backed by data from the real-world (RW) cohorts. Thanks to the compelling evidence and the edge of convenience, the IRd regimen has been widely adopted in clinical practice and helped bring the disease under control for managing rrMM patients. In an interview with Omnihealth Practice, Dr. Lau, Chi-Kuen shared a clinical case of an rrMM patient achieving a very good clinical response and has been on the IRd treatment for more than 3 years, demonstrating the effectiveness of IRd in local practice.

The standard treatment for physically fit and young patients with advanced chronic lymphocyticleukemia (CLL) and genetic risk factors is the chemoimmunotherapy (CIT) regimen of fludarabine+ cyclophosphamide + rituximab or bendamustine + rituximab, especially in many Europeancountries, where the continuous treatment with Bruton tyrosine kinase inhibitors (BTKi), such asibrutinib, is approved but not reimbursed.¹ In unfit patients, trials have shown greater improvementsin progression-free survival (PFS) with venetoclax + obinutuzumab as a time-limited therapycompared with chlorambucil + obinutuzumab.¹ Other phase 2 trials also demonstrated remarkableimprovements in the undetectable minimal residual disease (MRD) rates with the triple combinationconsisting of adding BTKi to venetoclax + obinutuzumab.¹

Multiple myeloma (MM) is the second most common hematological malignancy and is associated with significant morbidity due to its end-organ destruction.¹ Despite significant treatment advances in the past couple decades, MM remains an incurable malignancy with most patients eventually experience rela

Although the median overall survival (OS) of patients with multiple myeloma (MM) has significantly improved over the past two decades, MM remains an incurable malignancy with most patients experiencing relapse and requiring additional therapy.¹ Among these patients, the presence of clonal heterogeni